People with missing teeth may be able to grow new ones, say local dentists testing a pioneering drug they hope will offer an alternative to dentures and implants.
Unlike reptiles and fish, which usually replace their fangs on a regular basis, it is widely accepted that humans and most other mammals only grow two sets of teeth.
But hidden underneath our gums are the dormant buds of a third generation, according to Katsu Takahashi, head of oral surgery at the Medical Research Institute Kitano Hospital in Osaka.
His team launched clinical trials at Kyoto University Hospital in October, administering an experimental medicine to adult test subjects that they say has the potential to jumpstart the growth of these concealed teeth.
It is a technology that is “completely new” to the world, according to Takahashi.
Prosthetic treatments used for teeth lost to decay, disease or injury are often seen as costly and invasive.
So “restoring natural teeth definitely has its advantages”, said Takahashi, the project’s lead researcher.
Tests on mice and ferrets suggest that blocking a protein called USAG-1 can awaken the third set, and the researchers have published lab photographs of regrown animal teeth.
In a study published last year, the team said their “antibody treatment in mice is effective for tooth regeneration and can be a breakthrough in treating tooth anomalies in humans”.
For now, the dentists are prioritising the “dire” needs of patients with six or more permanent teeth missing from birth.
The hereditary condition is said to affect around 0.1% of people, who can have severe trouble chewing, and in Japan often spend most of their adolescence wearing a face mask to hide the wide gaps in their mouth, Takahashi said.
“This drug could be a game- changer for them,” he added.
The drug is therefore aimed primarily at children.
The researchers want to make it available as early as 2030.
A confident Takahashi argues that the location of a new tooth in a mouth can be controlled, if not pinpointed, by the drug injection site.
And if it grows in the wrong place, it can be moved through orthodontics or transplantation, he said.
No young patients with the congenital disorder are taking part in the first clinical trial, as the main objective is to test the drug’s safety, rather than its effectiveness.
So for now, the participants are healthy adults who have lost at least one existing tooth.
And while tooth regeneration is not the express goal of the trial this time around, there is a slim chance that it could happen to subjects anyway, Takahashi said.
If so, the researchers will have confirmed that the drug can be effective for those with acquired toothlessness, which would be a medical triumph.
“I would be over the moon if that happens,” Takahashi said. — AFP